Search results
19 paź 2021 · Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard-of-care in MBC but may be supplemented with locoregional treatments (LRTs) according to the disease status of the individual patient.
- Ok
Full Text (PDF) Scopus (125) PubMed. Google Scholar. 16. ......
- Are We Finally There
Over the past decade, tumor molecular characterization using...
- Volume 32, ISSUE 12
Full-Text HTML; PDF PARP inhibitor sensitivity in...
- VP3-2023
NATALEE showed a statistically significant invasive...
- Atalante-1
Patients with advanced non-small-cell lung cancer (NSCLC)...
- EV-301 Long-term Outcomes
The 5-year relative survival rate in patients with...
- Newly Diagnosed and Relapsed Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) represents a heterogeneous...
- Management of Toxicities From Immunotherapy
KJ reports personal fees as an invited speaker from Amgen,...
- Ok
25 paź 2022 · This ESMO Clinical Practice Guideline provides key recommendations for managing metastatic colorectal cancer. •. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. •. Treatment algorithms for locoregional, advanced/metastatic and recurrent advanced colorectal cancer are provided. •.
13 kwi 2023 · Metastasis is the most lethal manifestation of cancer, but our understanding of its biology and how to effectively treat it is rapidly advancing. This review highlights established and emerging principles of metastasis and provides a framework to develop more effective therapies for metastatic cancer.
1 gru 2022 · Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from metastatic disease. Combating cancer metastasis and post-therapeutic recurrence successfully requires understanding each step of metastatic progression.
19 paź 2021 · The use of chemotherapy (ChT), with or without immune checkpoint inhibitor (ICI) therapy according to programmed death-ligand 1 (PD-L1) status, or targeted therapies such as anti-body-drug conjugates (ADCs) should be considered for pa-tients with metastatic triple-negative breast cancer (mTNBC).
12 mar 2020 · Introduction. The development of secondary tumors in a part of the body that is far from the original primary cancer is termed “metastasis.” Despite metastasis being the key cause of failure of...
This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing metastatic breast cancer. It covers diagnosis, staging, risk assessment, treatment, disease monitoring, palliative care and the patient perspective.
